Company profile TOVX

Theriva Biologics Inc
synthetic biologics, inc. (nyse mkt: syn) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. the company's lead candidates poised for phase 3 development are: (1) syn-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause... of irritable bowel syndrome with constipation (ibs-c), and (2) syn-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (iv) beta-lactam antibiotics for the prevention of c. difficile infection (cdi), antibiotic-associated diarrhea (aad) and the emergence of antimicrobial-resistance (amr). the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (pku). Show More
Quarter analysis & expected interestLast update: February 09 2024 16:20:44.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Theriva Biologics expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
20190
113
inf% QoQ
0
-100.0% QoQ
63
inf% QoQ
2020 96
inf% YoY 52.4% QoQ
126
11.5% YoY 31.2% QoQ
220
inf% YoY 74.6% QoQ
120
90.5% YoY -45.5% QoQ
2021 244
154.2% YoY 103.3% QoQ
129
2.4% YoY -47.1% QoQ
80
-63.6% YoY -38.0% QoQ
210
75.0% YoY 162.5% QoQ
2022 170
-30.3% YoY -19.0% QoQ
91
-29.5% YoY -46.5% QoQ
95
18.8% YoY 4.4% QoQ
64
-69.5% YoY -32.6% QoQ
2023 86
-49.4% YoY 34.4% QoQ
20
-78.0% YoY -76.7% QoQ
95
0.0% YoY 375.0% QoQ
133
107.8% YoY 40.0% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Theriva Biologics search interestLast update: February 09 2024 16:20:43.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 16:20:45.

The average 5 years interest of Theriva Biologics was 8.26 per week.
The last year interest of Theriva Biologics compared to the last 5 years has changed by -38.26%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -2.49%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SYN-004 to provide analysis

Correlation between past revenue and SYN-004 search interest

There is not enough data for SYN-004 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SYN-004 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SYN-020 to provide analysis

Correlation between past revenue and SYN-020 search interest

There is not enough data for SYN-020 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SYN-020 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VCN-01 to provide analysis

Correlation between past revenue and VCN-01 search interest

There is not enough data for VCN-01 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VCN-01 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SYN-006 to provide analysis

Correlation between past revenue and SYN-006 search interest

There is not enough data for SYN-006 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SYN-006 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SYN-007 to provide analysis

Correlation between past revenue and SYN-007 search interest

There is not enough data for SYN-007 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SYN-007 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SYN-005 to provide analysis

Correlation between past revenue and SYN-005 search interest

There is not enough data for SYN-005 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SYN-005 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VCN-11 to provide analysis

Correlation between past revenue and VCN-11 search interest

There is not enough data for VCN-11 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VCN-11 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Theriva Biologics stock price to provide analysis

Correlation between past revenue and Theriva Biologics stock price search interest

There is not enough data for Theriva Biologics stock price to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Theriva Biologics stock price to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for TOVX
Earnings date: 2024-02-22 After close
Company name: Theriva Biologics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-05T20:30:00Z

GlobeNewswire
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

2026-04-17T20:05:00Z

GlobeNewswire
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

2026-03-31T20:57:46Z

Analyst Upgrades
Maxim Group Upgrades Theriva Biologics to Buy, Announces $1 Price Target

2026-03-23T12:00:00Z

GlobeNewswire
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

2026-03-12T12:00:00Z

GlobeNewswire
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

2026-02-19T16:00:26Z

GlobeNewswire
$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum

2026-02-18T13:00:00Z

GlobeNewswire
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications

2026-02-03T13:00:00Z

GlobeNewswire
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026

2025-12-29T13:00:00Z

GlobeNewswire
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

2025-11-12T13:00:00Z

GlobeNewswire
Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results

2025-10-24T18:31:47Z

GlobeNewswire
Theriva Biologics Provides Response to Unusual Market Action

2025-10-20T07:22:41-04:00

SEC
8-K Form - Current report, items 8.01 and 9.01 - Theriva Biologics, Inc. (0000894158) (Filer)

2025-10-17T17:19:25-04:00

SEC
8-K Form - Current report, items 1.01, 3.02, 8.01, and 9.01 - Theriva Biologics, Inc. (0000894158) (Filer)

2025-10-16T17:00:34-04:00

SEC
424B5 Form - Prospectus [Rule 424(b)(5)] - Theriva Biologics, Inc. (0000894158) (Filer)

2025-10-16T17:00:24-04:00

SEC
424B5 Form - Prospectus [Rule 424(b)(5)] - Theriva Biologics, Inc. (0000894158) (Filer)